Trump credits therapeutics for COVID-19 recovery, says drugs will be made widely available – National

Trump credits therapeutics for COVID-19 recovery, says drugs will be made widely available - National



U.S. President Donald Trump, in a video posted on Twitter on Wednesday, credited Regeneron Pharmaceuticals Inc. and Eli Lilly and Co therapeutics for his recovery from COVID-19, and said he wanted to make the drugs more widely available to the American public.“I felt good immediately,” Trump said in the video. “We have Regeneron, we have a very similar drug from Eli Lilly and they’re coming out, and we’re trying to get them on an emergency basis. We’ve authorized it. I’ve authorized it. And if you’re in the hospital and you’re feeling really bad, I think we’re going to work it so that you get them and you get them for free.”A MESSAGE FROM THE PRESIDENT! pic.twitter.com/uhLIcknAjT— Donald J. Trump (@realDonaldTrump) October 7, 2020 Story continues below advertisement

The president’s comments come the same day Eli Lilly and Co said it had applied for U.S. emergency use authorization (EUA) for its experimental COVID-19 antibody treatment and planned to pursue a similar approval for a dual antibody therapy next month after it produced promising data. [ Sign up for our Health IQ newsletter for the latest coronavirus updates ]
The drugmaker said its two-antibody cocktail helped reduce viral levels more than the single antibody treatment had in a prior study. The lower viral load was potentially tied to a reduction in COVID-19 symptoms, the company said.
Read more:
‘Fed up’: Trump losing support of key demographic ahead of election, polls show

“We believe that Lilly’s data provides some real evidence that the combo mAb (monoclonal antibody) approach may provide meaningful clinical benefits,” Baird analyst Brian Skorney said.

Trending Stories



Infected Trump seen ‘gasping’ from White House balcony before photo op



Kellyanne Conway scolds daughter Claudia for TikToks about Trump, COVID-19

Shares of the Indianapolis drugmaker were up more than 3 per cent.Data in September showed that Lilly’s single antibody therapy, LY-CoV555, which is being developed with Canadian biotech AbCellera, helped cut hospitalization and emergency room visits for COVID-19 patients.Based on that data, Lilly applied for an EUA with the U.S. Food and Drug Administration and said it expects about one million doses of the biotech drug to be available by the end of the year.Several drugmakers are testing antibody treatments for COVID-19 as a means of helping patients’ immune systems fight the virus. None of those drugs have been authorized for emergency use in the United States. Story continues below advertisement

1:49
Coronavirus: Trump pushes for COVID-19 stimulus cheques after initially stopping relief talks

Coronavirus: Trump pushes for COVID-19 stimulus cheques after initially stopping relief talks

An experimental dual-antibody cocktail developed by Regeneron Pharmaceuticals Inc was among the medicines given to Trump to treat his COVID-19.The company supplied the drug through a compassionate use program.Lilly chose not to distribute its experimental drug via a compassionate use program, preferring to recruit patients in need for its clinical trials due to the urgency to generate data showing that it works, Chief Executive David Ricks said on a conference call.
Read more:
University of Waterloo research considers who should get COVID-19 vaccine first

In the study involving 268 patients with mild-to-moderate COVID-19, nearly 1 per cent of those who received the Lilly dual-antibody therapy required hospitalization. That compared with 5.8 per cent who got a placebo, suggesting a clinically meaningful response. Story continues below advertisement

The combination therapy also met the trial’s main goal of significantly reducing the amount of virus present 11 days after treatment, compared with a placebo, Lilly said. The treatment also reduced viral levels at day three and day seven.

1:42
Trump returns to Oval Office after COVID-19 diagnosis

Trump returns to Oval Office after COVID-19 diagnosis

Lilly expects to supply 50,000 doses of the combination therapy in the fourth quarter.

View link »







Via Source link